Novavax

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 1.5K

Market Cap: $1.7B

Website

Introduction: Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Clinical Trials

Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine

Phase 1

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Biological: RSV-F Particle Vaccine
Biological: Placebo

First Posted Date: 2011-02-07

Last Posted Date: 2012-03-08

Lead Sponsor: Novavax

Target Recruit Count: 150

Registration Number: NCT01290419

Locations: 🇺🇸
Healthcare Discoveries d/b/a ICON Development Solutions, San Antonio, Texas, United States

Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) Vaccine

Phase 2

Completed

Conditions: Seasonal Influenza

Interventions: Biological: A/H1N1 2009 Influenza VLP Vaccine
Biological: Placebo

First Posted Date: 2010-02-22

Last Posted Date: 2012-04-25

Lead Sponsor: Novavax

Target Recruit Count: 4560

Registration Number: NCT01072799

Locations: 🇲🇽
Specialities Hospital, National Medical Centre "Siglo XXI" Mexican Institute for Social Security (IMSS), Mexico City, Mexico

Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Older Adults

Phase 2

Completed

Conditions: Influenza

Interventions: Biological: Influenza VLP Vaccine
Biological: TIV

First Posted Date: 2009-11-17

Last Posted Date: 2013-07-18

Lead Sponsor: Novavax

Target Recruit Count: 467

Registration Number: NCT01014806

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Coastal Carolina Research Center, Mt. Pleasant, South Carolina, United States
🇺🇸
Brown University, Providence, Rhode Island, United States

and more 3 locations

Trial to Evaluate Safety and Immunogenicity of Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant)

Phase 2

Completed

Conditions: Seasonal Influenza

Interventions: Biological: Placebo
Biological: Influenza VLP Vaccine

First Posted Date: 2009-05-18

Last Posted Date: 2013-07-18

Lead Sponsor: Novavax

Target Recruit Count: 221

Registration Number: NCT00903552

Locations: 🇺🇸
SNBL Clinical Pharmacology Center, Baltimore, Maryland, United States
🇺🇸
University Clinical Research, Inc., Pembroke Pines, Florida, United States

Evaluate the Safety and Immunogenicity of a Seasonal Influenza VLP Vaccine (Recombinant) in Healthy Adults

Phase 2

Completed

Conditions: Influenza

Interventions: Biological: Influenza VLP Vaccine (recombinant)
Biological: Placebo

First Posted Date: 2008-09-18

Last Posted Date: 2013-07-18

Lead Sponsor: Novavax

Target Recruit Count: 317

Registration Number: NCT00754455

Locations: 🇺🇸
Benchmark Research, Austin, Texas, United States
🇺🇸
The Center for Pharmacuetical Research, Kansas City, Missouri, United States
🇺🇸
Omega Medical Research, Warwick, Rhode Island, United States

and more 1 locations

Safety, Reactogenicity and Immunogenicity of an H5N1 VLP

Phase 1

Completed

Conditions: Pandemic Influenza

Interventions: Biological: H5N1 VLP Vaccine
Biological: Placebo

First Posted Date: 2007-08-22

Last Posted Date: 2013-06-21

Lead Sponsor: Novavax

Target Recruit Count: 230

Registration Number: NCT00519389

Locations: 🇺🇸
Healthcare Discoveries, Inc., San Antonio, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy